Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Pharmacological inhibition of SLC7A11 significantly causes tumor regression of PDAC and eliminates MCU-driven metastasis, suggesting that SLC7A11 may be a downstream target of the MCU-Nrf2 axis
The product should not be used by pregnant or breastfeeding women, nor by children and adolescents under 18 years of age
BPC-157 and TB-500 subsequently emerged as recognised research compounds due to their defined structures, reproducible analytical characteristics and suitability for controlled experimental investigations
JCO Clin Cancer Inform 8, 2024
General Potency: The other difference is potency (not to be confused with quality)
If youre in a hurry, check out our summary of recommendations below
US$ 26.50
US$ 29.79
US$ 26.88
